News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
677,336 Results
Type
Article (38705)
Company Profile (246)
Press Release (638385)
Section
Business (203346)
Career Advice (1974)
Deals (35343)
Drug Delivery (77)
Drug Development (80527)
Employer Resources (167)
FDA (15976)
Job Trends (14772)
News (343366)
Policy (32401)
Tag
Academia (2528)
Africa (710)
Alliances (48921)
Alzheimer's disease (1132)
Approvals (15922)
Arizona (169)
Artificial intelligence (64)
Asia (36698)
Australia (5967)
Bankruptcy (350)
Best Places to Work (11209)
Biosimilars (60)
Biotechnology (170)
C2C Services and Suppliers (78801)
California (1520)
Canada (829)
Cancer (319)
Career advice (1644)
Cell therapy (96)
China (109)
Clinical research (62886)
Collaboration (105)
Colorado (63)
Connecticut (59)
COVID-19 (2471)
Cystic fibrosis (71)
Data (124)
Diabetes (64)
Diagnostics (5940)
Drug pricing (59)
Earnings (83608)
Employer resources (140)
Europe (78378)
Events (107308)
Executive appointments (86)
FDA (16140)
Florida (207)
Funding (91)
Gene therapy (73)
GLP-1 (497)
Government (4282)
Healthcare (18569)
Hotbed/Location (480970)
Idaho (56)
Illinois (230)
Indiana (133)
Infectious disease (2495)
Inflammatory bowel disease (86)
Interviews (305)
IPO (16162)
Job creations (3618)
Job search strategy (1411)
Kansas (93)
Layoffs (388)
Legal (7827)
Lung cancer (69)
Manufacturing (71)
Maryland (336)
Massachusetts (1272)
Medical device (13012)
Medtech (13015)
Mergers & acquisitions (18985)
Metabolic disorders (213)
Michigan (114)
Minnesota (201)
Neuroscience (1241)
New Jersey (468)
New York (476)
NextGen Class of 2024 (6477)
Non-profit (4452)
North Carolina (554)
Northern California (693)
Obesity (132)
Ohio (96)
Opinion (167)
Patents (55)
Pennsylvania (511)
People (55683)
Pharmaceutical (59)
Phase I (19478)
Phase II (27698)
Phase III (20701)
Pipeline (91)
Postmarket research (2545)
Preclinical (8290)
Press Release (64)
Rare diseases (111)
Real estate (5878)
Recruiting (63)
Regulatory (21127)
Research institute (2300)
Resumes & cover letters (345)
South America (1084)
Southern California (624)
Startups (3554)
Texas (179)
United States (7260)
Vaccines (443)
Washington State (232)
Weight loss (116)
Date
Last 7 days (461)
Last 30 days (2176)
Last 365 days (37407)
2024 (24436)
2023 (40075)
2022 (51173)
2021 (55713)
2020 (54087)
2019 (46542)
2018 (35020)
2017 (32111)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26346)
2012 (28570)
2011 (29263)
2010 (27328)
677,336 Results for "tyme inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Syros and Tyme Technologies Announce Stockholder Approval of Merger
Syros Pharmaceuticals, Inc., a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022.
September 15, 2022
·
11 min read
Business
TYME Technologies, Inc. Announces Changes to its Board of Directors
TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced changes to its Board of Directors.
March 25, 2022
·
8 min read
Deals
Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its merger with Tyme Technologies, Inc., pursuant to which Syros acquired TYME, including its pipeline assets and net cash at closing of approximately $60 million.
September 16, 2022
·
9 min read
Business
TYME Technologies, Inc. Announces Exploration of Strategic Options
TYME Technologies, Inc., an emerging biotechnology company developing cancer metabolism-based therapies, announced that its Board of Directors has decided to explore potential strategic options to enhance stockholder value.
March 29, 2022
·
6 min read
Business
TYME Technologies, Inc. Reports Fourth Fiscal Quarter and Full Year 2022 Financial and Operating Results-- $84.0 million in cash and marketable securities as of March 31, 2022 --
TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its fourth fiscal quarter and full year ended March 31, 2022.
May 25, 2022
·
10 min read
Business
TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results
TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its third fiscal quarter ended December 31, 2021.
February 11, 2022
·
15 min read
Business
TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET
TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET.
January 27, 2022
·
2 min read
Pharm Country
TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer
TYME Technologies, Inc. today announced the discontinuation of SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer.
January 26, 2022
·
8 min read
Drug Development
TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections
TYME-19 demonstrated an antiviral effect against SARS CoV-2 in human lung epithelial cells, a model frequently used for drug screening for antiviral efficacy.
December 14, 2021
·
9 min read
Pharm Country
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022
TYME Technologies, Inc. today announced the availability of the poster abstract, “SM-88, D/L-alpha-metyrosine, is a novel anti-cancer agent in estrogen receptor positive breast cancer,” which was submitted by researchers from Georgetown University.
March 9, 2022
·
8 min read
1 of 67,734
Next
